替比夫定治疗育龄期男性慢性乙型肝炎患者的效果观察

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (40 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the effect and adverse reaction of Telbivudine in the treatment of child-bearing period male patients with chronic hepatitis B.Methods68 cases of chronic hepatitis B from January to December in 2013 in our hospital were selected and divided into the treatment group(36 cases)and the control group(32 cases)according to different treatment methods.The treatment group was given Telbivudine therapy on the basis of liver protection and enzyme reduction,the control group was given only liver protection and enzyme reduction.The effect of the two groups was compared.ResultsThe level of HBV-DNA in the treatment group at 12,24 and 48 weeks was lower than that in the control group,with significant difference(P＜0.01).There was no significant difference in the ALT recover normal rate between the two groups at 4 and 8 weeks(P＞0.05).The recovery normal rate of ALT in the treatment group at 12 and 24 weeks was higher than that in the control group,with significant difference(P＜0.05).There was no significant difference in the HBsAg positive rate of the two groups at birth,6 months after birth and 12 months after birth (P＞0.05). There were 2 cases with elevated creatine kinase in the treatment group,all of which were elevated below grade 2,and there was 1 case of dizziness and nausea at first weeks of treatment.ConclusionTelbivudine has antiviral effect with relatively high efficiency,with less adverse reaction,it is safe for male of childbearing age.

Key words： Telbivudine Child-bearing period Curative effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Song Hui ping

Cite this article:

Song Hui ping. Effect observation of Telbivudine in the treatment of child-bearing period male patients with chronic hepatitis B[J]. 中国当代医药, 2017, 24(14): 118-121.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I14/118

[1]	Van BF，Berg T.Antiviral therapy of chronic hepatitis B[J].J Hepatol，2014，57（3-4）：206-215.
[2]	张伦理.WHO慢性乙型肝炎预防、护理和治疗指南（2015）：治疗部分[J].国际流行病学传染病学杂志，2015，42（2）：73-75.
[3]	Sarin SK，Kumar M，Lau GK，et al.Asian-pacific clinical practice guidelines on the management of hepatitis B：a 2015 updat[J].Hepatol Int，2016，10（1）：1-98.
[4]	Terrault NA，Bzowej NH，Chang K，et al.AASLD guidelines for treatment of chronic hepatitis B[J].Hepatology，2015，63 （1）：261-283.
[5]	中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南[J].中华传染病杂志，2011，29（2）：65-80.
[6]	中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2015更新版）[J].中华肝脏病杂志，2015，23（12）：888-905.
[7]	Bridges EG，Selden JR，Luo S.Nonclinical safety profile of telbivudine，anovelpotentantiviralagentfortreatmentofhepatitis B[J].Antimicrob Agents Chemother，2008，52（7）：2521-2528.
[8]	潘静，陆伦根.核苷（酸）类似物初始治疗慢性乙型肝炎患者疗效和安全性的网络Meta分析[J].实用肝脏病杂志，2017，20（1）：29-33.
[9]	Sun J，Xie Q，Tan D，et al.The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients：a randomized，controlled study[J].J Hepatology，2014，59（4）：1283-1292.
[10]	张俊明，李国敏，洪宝林，等.预防免疫阻断乙型肝炎病毒父婴传播播的临床研究[J].实用临床医药杂志，2009，13（19）：134-135.
[11]	朱科伦，朱郇悯，曾文铤，等.HBV经生殖细胞传播的研究[J].广州医药，2008，39（2）：3-5.
[12]	张荣莲，罗颖，谢婧娴，等.HBV父婴垂直传播水平与HBV DNA载量的相关研究[J].中华流行病学杂志，2010，31（2）：159-162.
[13]	Liaw YF，Gane E，Leung N，et al.2-year GLOBE trial results：telbivudine is superior to lamivudine in patients with chronic hepatitis B[J].Gastroenterology，2009，136（2）：486-495.
[14]	Zou XJ，Jiang XQ，Tian DY.Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine[J].J Viral Hepatitis，2011，18（12）：892-896.
[15]	Goncalves J，laeufle R，Avila C.Increased risk with combination of telbivudine and pegylated-interferon alfa-2a in study CLDT600A2406 compared to uncommon rate with telbivudine monotherapy from the novartis global database [J].J Hepatol，2009，50（9）：S329-S330.